Celsis IVT and Promega to Offer Solutions for ADME-Tox Testing with Primary Hepatocytes
News Feb 10, 2009
Celsis In Vitro Technologies (Celsis IVT), a division of Celsis International plc, and Wisconsin-based Promega Corp will take the trial and guesswork out of ADME-Tox testing in primary hepatocytes.
Celsis IVT is pre-qualifying lots of its extensive cryopreserved hepatocytes for use with Promega's bioluminescent ADME-Tox assays, including the P450-Glo™ CYP Assay used to study cytochrome P450 gene induction and inhibition and the GSH-Glo™ Glutathione Assay for investigating mechanisms of hepatotoxicity.
"Researchers are looking for validated solutions that are predictive," said Dr. James Cali, lead scientist for ADME-Tox at Promega. "Providing pre-qualified cryoplateable hepatocytes that work the first time and every time with our luminescent reagents has always been a goal for Promega. By validating lots from their extensive inventory in advance, Celsis IVT will help our customers save additional time in their research," he explained. "Together, we are taking the guesswork out of hepatocyte analysis."
Determining whether a particular lot of hepatocytes will work for a given application is time-consuming and costly. Much of the effort involves trial and error. Even when a suitable lot of hepatocytes is identified, current LC/MS technologies for measuring gene expression, enzyme activity or metabolite formation are expensive or require lengthy incubations times that often involve working evening or weekend hours.
This collaborative effort between Promega and Celsis IVT will enable customers to identify and select both products that have been validated to work together, saving customers valuable time and resources, leading to the faster development of safe drugs.
The two companies are collaborating on scientific presentations and publications demonstrating effective applications of the validated tools for ADME-Tox studies.